Global X Longevity Thematic
ALTAR
Score™
3.3% info Recommen-
dation
UNDERWEIGHT
2019E    2020E
P/E
ratio
28.6x P/Sales
ratio
3.4x
P/BV
ratio
4.0x Div.
yield
1.3%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
Global X Longevity Thematic ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the Indxx Global Longevity Thematic Index.

FUND BASICS
Category Global Equities
Fund Sponsor Global X
Website www.globalxfunds.com
Inception date May 10, 2016
Assets (mns) $24
Currency USD
Expense ratio 50 bp
Distributions Annually

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian
Weighting Market Cap
Index replication
Uses derivatives No
Options available No

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 98
Wgt avg mkt cap (mns) $45,863
Large cap (>$10bn) 76.6%
Mid cap ($2-10bn) 16.8%
Small cap (<$2bn) 5.6%
Developed mkts 98.1%
Emerging mkts 1.9%

TOP TEN HOLDINGS
CHUGAI PHARMACEUTICAL CO LTD 4.0 %
EDWARDS LIFESCIENCES CORP 3.7 %
MEDTRONIC PLC 3.6 %
BIOGEN IDEC INC 3.6 %
BRISTOL-MYERS SQUIBB CO 3.6 %
AMGEN INC 3.4 %
VERTEX PHARMACEUTICALS INC 3.3 %
BOSTON SCIENTIFIC CORP 3.2 %
NOVO NORDISK A/S-B 3.1 %
ABBVIE INC 3.0 %
Total 34.5 %

TOP COUNTRY EXPOSURE
UNITED STATES 64.7 %
JAPAN 7.5 %
DENMARK 6.1 %
IRELAND 4.3 %
BRITAIN 3.0 %
SWITZERLAND 2.5 %
FRANCE 1.9 %
GERMANY 1.9 %
SOUTH KOREA 1.7 %
BELGIUM 1.3 %

HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru November 30)
Year-to-date 1 year 5 years 10 years Since Incep.
25.4% 15.7% -- -- 13.6%

Market Correlations
versus... Beta R-squared
S&P500 0.94 61%
MSCI EAFE 0.85 42%
MSCI Emg. Mkts. 0.65 39%

Technical Indicators
Recent close $23.69
30d moving avg. $23.03
Annualized volatility 14.5%
Short interest (ETF) 1.0%
Relative strength (RSI) 70

Liquidity measures
Avg. volume (thou.) 3
Turnover 0.3%
Bid/Ask (% of price) 1.22%
ADV underlying (mns) $10,604

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the Global X Longevity Thematic ETF based on the alternatives' overlap in portfolio holdings with LNGR. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: LNGR Expense: 50 bp ALTAR Score™: 3.3%


ALTERNATIVE ETFs BASED ON OVERLAP WITH LNGR
Ticker Fund
Name
Overlap1
vs LNGR
(%)
Expense
ratio
(bp)
Savings
vs LNGR
(bp)
ALTAR
Score™
(%)
ALTAR
vs LNGR
(%)
RYH Invesco S&P Equal Weight Healthcare 29.1 40 10 7.0 +3.7
IYH iShares US Healthcare 29.0 43 7 6.3 +2.9
FHLC Fidelity MSCI Health Care 28.2 8 42 5.8 +2.5
GDNA Goldman Sachs Motif Human Evolution 27.4 50 0 1.0 -2.3
XLV Health Care Select Sector SPDR 27.4 13 37 7.2 +3.9
VHT Vanguard Health Care 27.0 10 40 5.9 +2.6
IEIH iShares Evolved U.S. Innovative Healthcare 26.2 18 32 4.4 +1.1
JHMH John Hancock Multifactor Health Care 26.1 40 10 6.6 +3.3
IHI iShares DJ US Medical Devices 25.2 43 7 3.8 +0.5
IEHS iShares Evolved U.S. Healthcare Staples 24.8 18 32 5.9 +2.6
IBB iShares NASDAQ Biotechnology 23.2 47 3 0.4 -2.9
IXJ iShares S&P Global Healthcare 23.1 46 4 6.4 +3.0
FXH First Trust Health Care Alphadex 21.9 63 -13 7.1 +3.7
HTEC Robo Global Healthcare Technology and Innovation 20.1 68 -18 -0.0 -3.4
FBT First Trust NYSE-ARCA Biotechnology 19.7 57 -7 -0.7 -4.1
XHE SPDR S&P Health Care Equipment 19.5 35 15 2.1 -1.2
BBH VanEck Vectors Biotech 19.2 35 15 4.5 +1.2
XBI SPDR S&P Biotech ETF 18.6 35 15 -4.4 -7.8
BBP BioShares Biotech Products 16.0 79 -29 -3.7 -7.0
PJP Invesco Dynamic Pharmaceuticals 16.0 56 -6 9.4 +6.1

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
Global X Longevity Thematic
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

UNDERWEIGHT

Below average appreciation potential. A rating of UNDERWEIGHT is assigned to ETFs with ALTAR Scores in the 2nd quintile (ranking higher than only 20%-40%) of their category. Typically, funds in this category consist of stocks trading at relatively expensive valuations and/or having below-average fundamentals.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity 13.6 %
Divided by: Fwd. P/BV 3.6 x
Less: Expense ratio 50 bp
Equals: ALTAR Score 3.3 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.55 CATEGORY
AVERAGE
1.55
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.